ATE245648T1 - 1h-pyrazolo(3,4-d)pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen - Google Patents
1h-pyrazolo(3,4-d)pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellenInfo
- Publication number
- ATE245648T1 ATE245648T1 AT98917859T AT98917859T ATE245648T1 AT E245648 T1 ATE245648 T1 AT E245648T1 AT 98917859 T AT98917859 T AT 98917859T AT 98917859 T AT98917859 T AT 98917859T AT E245648 T1 ATE245648 T1 AT E245648T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- pyrazolo
- propulation
- dione
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9701398A SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Novel compounds |
| PCT/SE1998/000640 WO1998046606A1 (en) | 1997-04-15 | 1998-04-07 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE245648T1 true ATE245648T1 (de) | 2003-08-15 |
Family
ID=20406576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98917859T ATE245648T1 (de) | 1997-04-15 | 1998-04-07 | 1h-pyrazolo(3,4-d)pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6028074A (de) |
| EP (1) | EP0975636B1 (de) |
| JP (1) | JP2001520645A (de) |
| KR (1) | KR20010006350A (de) |
| CN (1) | CN1259951A (de) |
| AT (1) | ATE245648T1 (de) |
| AU (1) | AU733066B2 (de) |
| BR (1) | BR9808540A (de) |
| CA (1) | CA2286078A1 (de) |
| DE (1) | DE69816608T2 (de) |
| EE (1) | EE9900465A (de) |
| HU (1) | HUP0002104A3 (de) |
| ID (1) | ID22746A (de) |
| IL (1) | IL132153A0 (de) |
| IS (1) | IS5198A (de) |
| NO (1) | NO995006L (de) |
| PL (1) | PL336230A1 (de) |
| SE (1) | SE9701398D0 (de) |
| SK (1) | SK135699A3 (de) |
| TR (1) | TR199902538T2 (de) |
| WO (1) | WO1998046606A1 (de) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801399D0 (sv) | 1998-04-21 | 1998-04-21 | Astra Pharma Prod | Method and apparatus for filling containers |
| GC0000177A (en) * | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| JP2004527541A (ja) | 2001-03-01 | 2004-09-09 | スミスクライン・ビーチャム・コーポレイション | トロンボポエチン模倣物 |
| CA2459161A1 (en) | 2001-08-31 | 2003-03-13 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain |
| MY142390A (en) | 2002-05-22 | 2010-11-30 | Glaxosmithkline Llc | 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| TW200526638A (en) | 2003-10-22 | 2005-08-16 | Smithkline Beecham Corp | 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline |
| WO2006127918A2 (en) * | 2005-05-24 | 2006-11-30 | Ott David M | Personal care and medicinal products incorporating bound organosulfur groups |
| AU2006255028B2 (en) | 2005-06-06 | 2012-04-19 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2023729B1 (de) | 2006-06-06 | 2016-05-04 | Intra-Cellular Therapies, Inc. | Organische verbindungen |
| US9198924B2 (en) | 2006-11-13 | 2015-12-01 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
| ECSP077628A (es) | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
| KR20100094551A (ko) * | 2007-12-06 | 2010-08-26 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| JP5068857B2 (ja) | 2007-12-06 | 2012-11-07 | 武田薬品工業株式会社 | 有機化合物 |
| JP5778582B2 (ja) | 2008-12-06 | 2015-09-16 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| EP2358723B1 (de) | 2008-12-06 | 2015-05-13 | Intra-Cellular Therapies, Inc. | 4,5,7,8-Tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidin-Verbindungen als PDE1 Inhibitoren |
| JP5813511B2 (ja) * | 2008-12-06 | 2015-11-17 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| US8927556B2 (en) | 2008-12-06 | 2015-01-06 | Intra-Cellular Therapies, Inc. | 1H-pyrrolo[3,4-D]pyrimidin-2(6H)-one compounds |
| JP5784501B2 (ja) | 2008-12-06 | 2015-09-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| AU2009322905A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2012518685A (ja) | 2009-02-25 | 2012-08-16 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 眼障害のためのｐｄｅ１阻害剤 |
| US8623880B2 (en) | 2009-03-23 | 2014-01-07 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as TRPA1 modulators |
| KR20110128898A (ko) | 2009-03-23 | 2011-11-30 | 그렌마크 파머수티칼스 에스. 아. | Ｔｒｐａ1 조절자로서 푸로피리미딘디온 유도체 |
| EA201190191A1 (ru) | 2009-03-23 | 2012-11-30 | Гленмарк Фармасьютикалс, С.А. | Изотиазоло-пиримидинедионовые производные в качестве модуляторов trpa1 |
| JP5657638B2 (ja) * | 2009-03-23 | 2015-01-21 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔｒｐａ１調節因子としての縮合ピリミジンジオン誘導体 |
| WO2010132127A1 (en) | 2009-05-13 | 2010-11-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20120015355A (ko) | 2009-05-29 | 2012-02-21 | 글락소스미스클라인 엘엘씨 | 트롬보포이에틴 효능제 화합물의 투여 방법 |
| SG178279A1 (en) | 2009-08-05 | 2012-03-29 | Intra Cellular Therapies Inc | Novel regulatory proteins and inhibitors |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| WO2011153136A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2590657A4 (de) | 2010-05-31 | 2014-02-12 | Intra Cellular Therapies Inc | Organische verbindungen |
| EP2576551A4 (de) | 2010-05-31 | 2014-04-16 | Intra Cellular Therapies Inc | Organische verbindungen |
| WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP5989900B2 (ja) | 2012-06-08 | 2016-09-07 | グレンマーク ファーマシューティカルズ， エセ．アー． | ２−アミノ−４−アリールチアゾール化合物のアミド及びその塩類 |
| JP6549040B2 (ja) | 2013-02-17 | 2019-07-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規使用 |
| US9545406B2 (en) | 2013-03-15 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Method of treating a CNS injury with a PDE1 inhibitor |
| JP6437519B2 (ja) | 2013-03-15 | 2018-12-12 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| JP6696904B2 (ja) | 2014-01-08 | 2020-05-20 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 製剤および医薬組成物 |
| US9884872B2 (en) | 2014-06-20 | 2018-02-06 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| WO2016022893A1 (en) | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR102332957B1 (ko) | 2014-09-17 | 2021-11-29 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 화합물 및 방법 |
| BR112017012005B1 (pt) | 2014-12-06 | 2023-04-04 | Intra-Cellular Therapies, Inc | Compostos orgânicos inibidores de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2 |
| JP6608934B2 (ja) | 2014-12-06 | 2019-11-20 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2017172795A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| WO2018015088A1 (en) * | 2016-06-23 | 2018-01-25 | F. Hoffmann-La Roche Ag | Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives |
| WO2018049417A1 (en) | 2016-09-12 | 2018-03-15 | Intra-Cellular Therapies, Inc. | Novel uses |
| US11839614B2 (en) | 2018-01-31 | 2023-12-12 | Intra-Cellular Therapies, Inc. | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression |
| WO2021046179A1 (en) | 2019-09-03 | 2021-03-11 | Intra-Cellular Therapies, Inc. | Novel compounds |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0077372A1 (de) * | 1981-04-22 | 1983-04-27 | Byk Gulden Lomberg Chemische Fabrik GmbH | NEUE PYRAZOLO(3,4-d)PYRIMIDINE, VERFAHREN ZU DEREN HERSTELLUNG UND SIE ENTHALTENDE ARZNEIMITTEL |
| US4603203A (en) * | 1983-12-14 | 1986-07-29 | Takeda Chemical Industries, Ltd. | 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof |
| EP0237289A3 (de) * | 1986-03-14 | 1988-07-27 | Takeda Chemical Industries, Ltd. | Pyrazolo[3,4-d]pyrimidinderivate, ihre Herstellung und Verwendung |
| AU690527B2 (en) * | 1992-12-17 | 1998-04-30 | Pfizer Inc. | Pyrazoles having CRF antagonist activity |
| TW370529B (en) * | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
-
1997
- 1997-04-15 SE SE9701398A patent/SE9701398D0/xx unknown
-
1998
- 1998-04-07 BR BR9808540-9A patent/BR9808540A/pt not_active IP Right Cessation
- 1998-04-07 HU HU0002104A patent/HUP0002104A3/hu unknown
- 1998-04-07 KR KR1019997009435A patent/KR20010006350A/ko not_active Withdrawn
- 1998-04-07 WO PCT/SE1998/000640 patent/WO1998046606A1/en not_active Ceased
- 1998-04-07 ID IDW991207A patent/ID22746A/id unknown
- 1998-04-07 PL PL98336230A patent/PL336230A1/xx unknown
- 1998-04-07 CN CN98806075A patent/CN1259951A/zh active Pending
- 1998-04-07 JP JP54380398A patent/JP2001520645A/ja not_active Ceased
- 1998-04-07 CA CA002286078A patent/CA2286078A1/en not_active Abandoned
- 1998-04-07 AT AT98917859T patent/ATE245648T1/de not_active IP Right Cessation
- 1998-04-07 AU AU70909/98A patent/AU733066B2/en not_active Ceased
- 1998-04-07 DE DE69816608T patent/DE69816608T2/de not_active Expired - Fee Related
- 1998-04-07 IL IL13215398A patent/IL132153A0/xx unknown
- 1998-04-07 TR TR1999/02538T patent/TR199902538T2/xx unknown
- 1998-04-07 SK SK1356-99A patent/SK135699A3/sk unknown
- 1998-04-07 EE EEP199900465A patent/EE9900465A/xx unknown
- 1998-04-07 EP EP98917859A patent/EP0975636B1/de not_active Expired - Lifetime
- 1998-08-07 US US09/068,304 patent/US6028074A/en not_active Expired - Fee Related
-
1999
- 1999-09-27 IS IS5198A patent/IS5198A/is unknown
- 1999-10-14 NO NO995006A patent/NO995006L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001520645A (ja) | 2001-10-30 |
| US6028074A (en) | 2000-02-22 |
| AU733066B2 (en) | 2001-05-03 |
| CN1259951A (zh) | 2000-07-12 |
| WO1998046606A1 (en) | 1998-10-22 |
| KR20010006350A (ko) | 2001-01-26 |
| HUP0002104A2 (hu) | 2001-01-29 |
| AU7090998A (en) | 1998-11-11 |
| CA2286078A1 (en) | 1998-10-22 |
| ID22746A (id) | 1999-12-09 |
| EE9900465A (et) | 2000-04-17 |
| BR9808540A (pt) | 2000-05-23 |
| EP0975636A1 (de) | 2000-02-02 |
| NO995006D0 (no) | 1999-10-14 |
| PL336230A1 (en) | 2000-06-19 |
| IL132153A0 (en) | 2001-03-19 |
| IS5198A (is) | 1999-09-27 |
| EP0975636B1 (de) | 2003-07-23 |
| NO995006L (no) | 1999-10-14 |
| DE69816608T2 (de) | 2004-04-15 |
| TR199902538T2 (xx) | 2000-02-21 |
| SE9701398D0 (sv) | 1997-04-15 |
| SK135699A3 (en) | 2000-05-16 |
| DE69816608D1 (de) | 2003-08-28 |
| HUP0002104A3 (en) | 2002-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE245648T1 (de) | 1h-pyrazolo(3,4-d)pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen | |
| IS5082A (is) | Pýrróló[3,4-D]pýrimídínon-afleiður og notkun þeirra sem lyfja | |
| EE200000318A (et) | Uudsed ühendid | |
| NO20000311D0 (no) | Nye forbindelser | |
| MXPA04003668A (es) | Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos. | |
| SE9702001D0 (sv) | Novel compounds | |
| HUP0004211A2 (hu) | PDE-5 inhibitorok alkalmazása tüdõ magas vérnyomás kezelésére szolgáló gyógyszerkészítmények elõállítására | |
| PT828728E (pt) | Di-hidrobenzofuranos de fenilo | |
| ATE251908T1 (de) | Zusammensetzung zur behandlung sexueller funktionsstörungen die phosphodiesterase-5 inhibitoren enthaltend | |
| CY2462B1 (en) | Cyclohexyl dihydrobenzofuranes. | |
| CA2046755A1 (en) | /2r/-2-[di/2-propyl/phosphonylmethoxy]-3-p-toluenesulfonyloxy-1-trimethylacetoxypropane, its preparation and use | |
| GEP20094596B (en) | Compositions comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |